Table 1.

MIC/MBC of different antibiotics for the two clinical Pseudomonas aeruginosa strains.

Strains	MIC/MBC (mg/l)
	AMK	GEN	TIC	MEM	CAZ	FEP	SBT	CST	CIP	TGC
Pa147	1/2	>128/128	32/64	>128/>128	8/32	8/16	>128/>128	0.5/4	32/64	4/8
PaM1	4/16	1/2	1/32	0.25/2	≤0.25/2	2/32	128/>128	>128/>128	1/2	4/8

MIC, minimum inhibitory concentrations; MBC, minimum bactericidal concentration; AMK, amikacin; GEN, gentamicin; TIC, ticarcillin; MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; SBT, sulbactam; CST, colistin; CIP, ciprofloxacin; TGC, tigecycline. MIC results were interpreted according to EUCAST breakpoints: AMK, susceptible, MIC ≤ 8 mg/l and resistant MIC > 16 mg/l; GEN, susceptible, MIC ≤ 4 mg/l and resistant MIC > 4 mg/l; TIC, susceptible, MIC ≤ 16 mg/l and resistant MIC > 16 mg/l; MER, susceptible, MIC ≤ 2 mg/l and resistant MIC > 8 mg/l; CAZ and FEP, susceptible, MIC ≤ 8 mg/l and resistant MIC > 8 mg/l; CST, susceptible, MIC ≤ 2 mg/l and resistant MIC > 2 mg/l; CIP susceptible, MIC ≤ 0.5 mg/l and resistant MIC > 0.5 mg/l. Currently, there are no established susceptibility criteria in either EUCAST or CLSI for tigecycline and sulbactam in P. aeruginosa. Studies were performed in triplicate in different days.